ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia

ViCentra reported real-world EASD 2026 data from 3,918 adults with type 1 diabetes showing its Kaleido insulin-pump system achieved 72.2% time in target glucose range with minimal hypoglycemia. The results support the device's clinical effectiveness, though the release provides no financial metrics, regulatory action, or commercial guidance.